|
tbar.gif
Click
here to
submit entries
|
|
|
Amgen’s
Anemia Drugs Dealt Fresh Blows With One-Two Punch |
January
4, 2008--Two new studies indicate
that Amgen’s anemia drugs may increase the risk of death in some
patients. In recent years, six studies have found that the drugs (which
are erythropoietin-stimulating agents) can lead to an increased risk of
heart attack, stroke, heart failure, and cancer tumor growth in some
patients. The most recent studies may prompt the FDA to further restrict
the use of the drugs, which already carry a black-box warning. Los
Angeles Times
|
|
|
Genstruct: Patience, Persistence, and Payoff
By John Russell |
|
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.
Click
here
|
|
|
